The production of our special biotransformation mycelium raw materials has created the most favorable condition for development of all types of health care products. The company plans in the first period (2015-2017) to develop and market four categories and ten health care products.
Xinquan Xinlin, the parent company of Xindu Biological, has over 10 years of experience in the production and management of pharmaceuticals, with product quality QA / QC system and management advantages. The company appoints a technical director for product quality control, establishing and improving the management of all types of quality control systems.
Quality control will be ensured by a five-step management system
Starting from product development to conduct the “standards” checkpoint by meeting or exceeding the relevant health care quality standards promulgated by the US FDA
Substandard raw materials cannot be accepted for storage.
Substandard materials cannot enter the production pipeline.
Unqualified intermediate products cannot continue to the next production stage.
Products that failed QC cannot be stored and shipped for sale.